Evidence map›Paper›PMID 34425820›Full record

ArticleJournal of nanobiotechnology2021

Multifunctional AIE iridium (III) photosensitizer nanoparticles for two-photon-activated imaging and mitochondria targeting photodynamic therapy.

Xuzi Cai, Kang-Nan Wang, Wen Ma, Yuanyuan Yang, Gui Chen, Huijiao Fu, Chunhui Cui, Zhiqiang Yu, Xuefeng Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Cucurbit[8]uril-based supramolecular theranostics.Journal of nanobiotechnology · 2024
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xuzi Cai *Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510632, China.
Kang-Nan Wang *Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, 528308, Guangdong, China.
Wen MaGuangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
Yuanyuan YangGuangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
Gui ChenGuangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
Huijiao FuDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510632, China.
Chunhui CuiDepartment of General Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, 510250, China. drcuich@163.com.
Zhiqiang YuShunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, 528308, Guangdong, China. yuzq@smu.edu.cn.
Xuefeng WangDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510632, China. douwangxuefeng@163.com.

Funding

china postdoctoral science foundation 2019M662968guangdong basic and applied basic research foundation 2019A1515010452guangdong basic and applied basic research foundation 2019A1515110356guangdong basic and applied basic research foundation 2021A1515011050science and technology planning project of guangzhou city of china 202102080100
6 · The paper itself

Abstract

Developing novel photosensitizers for deep tissue imaging and efficient photodynamic therapy (PDT) remains a challenge because of the poor water solubility, low reactive oxygen species (ROS) generation efficiency, serve dark cytotoxicity, and weak absorption in the NIR region of conventional photosensitizers. Herein, cyclometalated iridium (III) complexes (Ir) with aggregation-induced emission (AIE) feature, high photoinduced ROS generation efficiency, two-photon excitation, and mitochondria-targeting capability were designed and further encapsulated into biocompatible nanoparticles (NPs). The Ir-NPs can be used to disturb redox homeostasis in vitro, result in mitochondrial dysfunction and cell apoptosis. Importantly, in vivo experiments demonstrated that the Ir-NPs presented obviously tumor-targeting ability, excellent antitumor effect, and low systematic dark-toxicity. Moreover, the Ir-NPs could serve as a two-photon imaging agent for deep tissue bioimaging with a penetration depth of up to 300 μm. This work presents a promising strategy for designing a clinical application of multifunctional Ir-NPs toward bioimaging and PDT.

Indexed as

AnimalsApoptosisCell DeathCell Line, TumorDiagnostic ImagingFemaleHydrogen-Ion ConcentrationIridiumMiceMice, Inbred BALB CMice, NudeMitochondriaNanoparticlesPhotochemotherapyPhotosensitizing AgentsIridiumPhotosensitizing AgentsCyclometalated iridium nanoparticlesFluorescence imagingMitochondria-targetedPhotodynamic therapyTwo-photon excitation

Identifiers

PMID34425820
PMCPMC8381541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.